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Multiple alignments of hepatitis C virus (HCV) polyproteins from six different genotypes identified a total of 22 noncon-
sensus mutations in a clone derived from the Hutchinson (H77) isolate. These mutations, collectively, may have contributed
to the failure in generating a “functionally correct” or “infectious” clone in earlier attempts. A consensus clone was
constructed after systematic repair of these mutations, which yielded infectious virions in a chimpanzee after direct
intrahepatic inoculation of in vitro transcribed RNAs. This RNA-infected chimpanzee has developed hepatitis and remained
HCV positive for more than 11 months. To further verify this RNA-derived infectivity, a second naive chimpanzee was injected
intravenously with serum collected from the first chimpanzee. Infectivity analysis of the second chimpanzee demonstrated
that the HCV infection was successfully transmitted, which validated unequivocally the infectivity of our repaired molecular
clone. Amino acid sequence comparisons revealed that our repaired infectious clone had 4 mismatches with the isogenic
clone reported by Kolykhalov et al. (1997, Science 277, 570–574) and 8 mismatches with that reported by Yanagi et al. (1997,
Proc. Natl. Acad. Sci. USA 94, 8738–8743). At the RNA level, more mismatches (43 and 67, respectively) were identified; most
of them were synonymous substitutions. Further comparisons with 16 isolates from different genotypes demonstrated that
our repaired clone shares greater consensus than the reported isogenic clones. This approach of generating infectious HCV
RNA validates the importance of amino acid sequence consensus in relation to the biology of HCV. © 1999 Academic Press
s
4
t
t
t
m
r
m
H
i
H
d
g
r
s
o
i
b
o
a
t
s
u
l
9
rINTRODUCTION
Hepatitis C virus (HCV) has been classified as a sep-
rate genus in the family of Flaviviridae (Choo et al., 1991;
iller and Purcell, 1990; Takamizawa et al., 1991), related
o flaviviruses, pestiviruses, and the newly discovered
B viruses (Simons et al., 1995) and hepatitis G virus
Linnen et al., 1996). HCV is the leading cause of post-
ransfusion hepatitis as well as community-acquired
on-A, non-B hepatitis with a high rate of chronicity (Alter
t al., 1989; Choo et al., 1989; Kuo et al., 1989). According
o the estimation from a recent World Health Organiza-
ion meeting, more than 170 million people worldwide
re infected with HCV. About 80% of patients with acute
CV infection will progress to chronic hepatitis; 20% of
hese will develop cirrhosis, and 1–5% of these will de-
elop hepatocellular carcinoma. The only therapy avail-
ble as of May 1998 for treating chronic HCV infection
as interferon (IFN)-a. However, only about 10% of pa-
ients have complete and sustained response in terms of
ormalization of serum alanine aminotransferase (ALT)
evel and loss of HCV RNA (Marcellin et al., 1997). In June
998, combination therapy of IFN-a and ribavirin, which
1 To whom correspondence and reprint requests should be ad-
ressed at Antiviral Therapy, K-15-4945, Schering-Plough Research
nstitute, 2015 Galloping Hill Road, Kenilworth, NJ 07033-0539. Fax:
s908) 740-3918. E-mail: zhi.hong@spcorp.com.
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36ignificantly improved the clinical outcomes with about
8% sustained response rate in patients who responded
o IFN-a monotherapy but relapsed after cessation of
herapy, was approved by the Food and Drug Adminis-
ration for this group of patients. Despite these advance-
ents, a significant portion of patients who have failed to
espond to these therapies are still waiting for newer and
ore effective antivirals.
Although biochemical characterization of individual
CV proteins or enzymes has revealed a number of
mportant features (Bartenschlager, 1997; Clarke, 1997;
oughton, 1996; Major and Feinstone, 1997; Rice, 1996),
ata on biological functions of HCV proteins in relation to
enetic analysis are limited. This is due to the lack of
eliable cell culture systems or small animal models that
upport HCV replication and, to a greater extent, the lack
f “biologically validated” molecular clones. To obtain an
nfectious HCV clone, tremendous amounts of effort have
een expended. Attempts to demonstrate the infectivity
f HCV clones in cell cultures (Dash et al., 1997; Yoo et
l., 1995) yielded results with skepticism, partly because
hese clones lacked the X region, a unique, highly con-
erved, 98-base sequence recently discovered at the 39
ntranslated region (UTR) of the HCV genome (Kolykha-
ov et al., 1996; Tanaka et al., 1996). This 39 conserved
8-base element (39X) is believed to play an important
ole in viral translation and replication. It has been
hown to enhance translation in cis by three- to fivefold
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37HCV INFECTIOUS CLONErom the internal ribosomal entry site of HCV RNA (Ito et
l., 1998). Despite the discovery of this novel 39X ele-
ent, initial studies using clones with 39X also failed to
emonstrate infectivity in chimpanzees (Kolykhalov et al.,
997). It was soon realized that mutations may have
ccurred during the isolation of molecular clones using
everse transcription coupled with polymerase chain re-
ction (RT-PCR). Such mutations may render the cDNA
lones to produce noninfectious RNA transcripts, similar
o experiences with other RNA viruses (Lai et al., 1991;
oormann et al., 1996). Two approaches were under-
aken to identify such mutations in HCV clones: (1)
olykhalov et al. (1997) sequenced 6 full-length cDNA
lones isolated independently from the H77 isolate to
dentify nonconsensus changes and built clones with a
onsensus sequence; (2) Yanagi et al. (1997) sequenced
8 HCV open reading frames (ORF) isolated from the
ame H77 isolate using long RT-PCR (Tellier et al., 1996),
dentified 6–28 potential mutations at the amino acid
evel in each clone, and constructed a clone with a near
onsensus sequence. In both cases, consensus clones,
epresenting a dominant viral sequence, were assem-
led, and in vitro transcribed RNAs from these clones
ere shown to be infectious and induced hepatitis in
himpanzees, the only animal model susceptible to HCV
nfection (Kolykhalov et al., 1997; Yanagi et al., 1997). In a
ecent report by Yanagi et al., a chimeric genome, which
onsists of the entire polyprotein of a genotype 1b isolate
HC-J4) placed in between the 59 and 39UTRs of a geno-
ype 1a isolate (H77), also yielded infectious RNA tran-
cripts. Interestingly, the chimpanzee infected with the
himeric clone did not develop hepatitis. These recent
dvancements in generating “infectious” clones will cer-
ainly impact the genetic studies on viral functions as
ell as the establishment of HCV replication systems.
RESULTS AND DISCUSSION
dentification of nonconsensus mutations
We describe here a computer-intensive approach to
dentify potential nonconsensus mutations, most of
hich are introduced by RT-PCR, a commonly used
ethod to isolate HCV clones. Two clones, pBRTM/HCV
-3011 (licensed from Dr. Charles M. Rice at Washington
niversity at St. Louis) and pRc/CMV/HCV-H (licensed
rom Dr. Alfred Prince at the New York Blood Center),
ere compared with 16 HCV isolates representing six
ajor HCV genotypes (Davidson et al., 1995). Twenty-one
onconsensus mutations or substitutions at the amino
cid level were identified throughout the entire HCV ORF
f pBRTM/HCV 1-3011 and one nonconsensus mutation
t the RNA level was found in the 59UTR of pRc/CMV/
CV-H. Representative mutations in the capsid region
nd the NS3 region are shown in Table 1 to exemplify the
riteria for the identification of such nonconsensus mu-ations, which emphasize those nonconserved mutations end mostly unique mutations of the pBRTM/HCV 1-3011
lone. The amino acids in red represent nonconsensus
utations found in the original pBRTM/HCV 1-3011
lone, designated HCV-1a(H/cr1). The corresponding
mino acids in blue from other HCV isolates (including 3
CV-1a subtypes, 6 HCV-1b subtypes, and 1 HCV-1c
ubtype) share consensus with each other but differ with
hose in pBRTM/HCV1-3011. In all cases but one, only
ne nucleotide change is required to introduce the mis-
atch, suggesting that these mutations may have been
ntroduced into the cDNA clones by RT-PCR. Interest-
ngly, the A-to-T (Ala to Thr) mutation in NS3 (at position
190 in the polyprotein, Table 1) renders the HCV pro-
ease domain less soluble and thus less active (Butk-
ewicz et al., 1996; Hong, unpublished data).
ystematic repair and assembly of a full-length HCV
DNA clone
Systematic repair of pBRTM/HCV 1-3011 was then
arried out. First, the entire HCV ORF was divided and
ubcloned into six plasmids, each containing a smaller
CV cDNA fragment (0.9–2.2 kb in size). The repair of
hese smaller plasmids was easier with the appropriate
hoice of restriction enzymes. Each mutation was cor-
ected by the following methods: (1) PCR-based mu-
agenesis; (2) synthetic polylinker-directed mutagenesis;
3) fragment swap from another isogenic clone, pRc/
MV/HCV-H, which lacks the mutation at the corre-
ponding region. In addition, the 59UTR with a preceding
7 promoter and SpeI site was added to the 59 end of the
apsid gene; and the 39UTR with a consensus sequence
a 133 poly(U/UC) tract plus the 98-base 39X region)
Kolykhalov et al., 1996) was synthesized (GenoSys Bio-
echnologies, Inc.) and placed at the end of the NS5B
egion followed by an XbaI site. Finally, the repaired
ragments were reassembled into a full-length clone,
amely, pET/T7/HCV-H. The full-length clone appears to
e stable in bacterial cells. No apparent rearrangement
as observed after serial passages (four times) at 30°C
unpublished data).
ntrahepatic transfection of a chimpanzee with RNA
ranscripts from the repaired clone
To produce full-length genomic RNA transcripts, the
ET/T7/HCV-H plasmid was linearized by XbaI digestion
ollowed by mung bean nuclease treatment. Mung bean
uclease removed the 59 overhangs and generated an
uthentic 39 end of the HCV genome. Notably, RNA tran-
cripts from XbaI linearized DNA without mung bean
uclease treatment (with four extra bases, CUAG, at the
9 end) were shown to be infectious (Yanagi et al., 1997).
illigram quantities of genome RNA transcripts were
roduced using a Large Scale T7 Transcription Kit (No-
agen, Inc.), which yields close to 80% full-length RNA as
stimated on an agarose gel. Approximately 150 mg of
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an amino acid identical to that at the corresponding position in HCV-1a(H/cr1).TABLE 2
Amino Acid Comparisons of the Repaired Clone with Clones from Other HCV Isolates
Note. HCV-1a(H/sp), (H/cr), and (H/nih) are all from the HCV-1a H77 isolate: (H/sp) denotes Schering-Plough in-house repaired clone; (H/cr) and
H/nih) represent the infectious clones reported previously (Kolyhalov et al., 1997; Yanagi et al., 1997). The sources for the rest of the clones and theTABLE 1
Identification of Potential RT-PCR Mutations by Multiple Alignments of Encoded HCV Protein Sequences from Six Major Genotypes
Note. HCV-1a(H/cr1) represents the original unrepaired clone, pBRTM/HCV 1-3011, isolated from the H77 strain, which was assembled and
haracterized (Grakoui et al., 1993); HCV-1a(H/ap) represents the clone pRc/CMV/HCV-H, isolated independently from the original Hutchinson isolate
Inchauspe et al., 1991). HCV-1a is the first clone discovered by Choo et al. (1989) at Chiron Corp. Sequences for HCV-1a(J1) (Okamoto et al., 1992a),
CV-1b(BK) (Takamizawa et al., 1991), HCV-1b(C2) (Wang et al., 1993), HCV-1b(J) (Kato et al., 1990), HCV-1b(JK1) (Honda et al., 1992), HCV-1b(JT)
Tanaka et al., 1992), HCV-1b(Taiwan) (Chen et al., 1992), HCV-1c (G9) (Okamoto et al., 1994), HCV-2a(J6) (Okamoto et al., 1991), HCV-2b(J8) (Okamoto
t al., 1992b), HCV-3a(NZL1) (Okamoto et al., 1993), HCV-3b(Tr Kj) (Chayama et al., 1994), HCV-4a(ED43) (Chamberlain et al., 1997b), HCV-5a(EUH1480)
Chamberlain et al., 1997a), and HCV-6a(EUHK2) (Adams et al., 1997) were retrieved from the GenBank data base. Three representative mutations
ere chosen to demonstrate our approach in identifying the critical RT-PCR induced mutations in the HCV-1a(H/cr1) clone. Amino acids at the
ocations where RT-PCR mutations were identified are color-coded: red, nonconsensus; blue, consensus; green, neutral changes. A dash representsonsensus comparisons are described in Table 1.
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39HCV INFECTIOUS CLONEhe in vitro transcribed HCV RNA was injected directly
nto three sites of a chimpanzee liver using an estab-
ished ultrasound-guided procedure described recently
Yanagi et al., 1998). Serum samples were collected
eekly from the chimpanzee (3262) and monitored for
iver enzyme (ALT) level, viremia, and anti-HCV antibod-
es.
The results in Fig. 1A demonstrated that the chimpan-
ee 3262 became infected at week 1 and HCV RNA was
etected in the serum by the SuperScript One-Step RT-
CR system (Life Technologies). Southern blot hybridiza-
ion analysis (Bassett et al., 1998) further confirmed the
dentity of the RT-PCR products (Fig. 1A). Weekly moni-
oring of the liver enzyme functions showed a character-
stic ALT profile of an HCV-infected chimpanzee (Fig. 1B):
small elevation at week 7 (ALT 74), followed by a
econd rise at weeks 12 and 13 (ALTs 171 and 151),
hich dropped to 37 at week 17. Serum HCV RNA was
uantifiable by the bDNA assay (Quantiplex-HCV RNA
.0, Chiron Corp., CA) at week 3, peaked at week 10–11,
nd dropped to below the detection limit (,0.2 3 106
enome equivalents/ml or 0.2 Meq/ml) at week 13 (Fig.
C). The level of circulating HCV RNA was barely detect-
ble at week 15 (Fig. 1A) and subsequently undetectable
t weeks 16 and 17 even by the RT-PCR/Southern blot
ybridization method, suggesting that the infected chim-
anzee may have suppressed the viral replication to a
ery low level. However, HCV RNA became detectable
gain at weeks 18–20 by RT-PCR, suggesting a rebound
f viral infection. This chimpanzee had since developed
chronic infection with fluctuations of viremia levels for
ore than 11 months. Interestingly, the changes in serum
LT and viremia levels coincide with the seroconversion
o anti-HCV at week 13 (Fig. 1D), similar to the timing
eported by Kolykhalov et al. (1997).
uthentication of the repaired clone
Unique molecular markers were built into the repaired
lone, pET/T7/HCV-H, to facilitate verification of the in-
ection. RT-PCR fragments isolated from chimpanzee
era spanning these markers were either sequenced
irectly or cloned (.20 clones isolated) and sequenced.
he sequence data confirmed the origin of the circulating
CV, which could have originated only from the RNA
ranscripts inoculated into the chimpanzee.
ransmission of RNA-induced HCV infection to a
aive chimpanzee
To further verify the RNA-derived infectivity in chim-
anzee 3262, serum collected at week 5 post-RNA in-
culation was injected intravenously into a second naive
himpanzee (3261). This chimpanzee (3261) became
nfected at week 1 (RT-PCR positive and quantifiable by
he bDNA assay). Weekly monitoring of the serum ALT
evels showed that the animal developed hepatitis with a dingle ALT rise peaking at week 9 (ALT 166) (Fig. 2A).
esults from the bDNA assay revealed that chimpanzee
261 had a detectable level (.0.2 Meq/ml) of circulating
CV at week 1. The viremia levels kept increasing with
ime, peaked at week 8, and then dropped to below the
FIG. 1. Infectivity analysis of RNA-infected chimpanzee 3262. (A)
T-PCR/Southern hybridization analysis of circulating HCV RNA. A plus
ign represents a positive control for serum HCV RNA. (B) Weekly
onitoring of serum ALT levels. The gray area represents normal range
f ALT values in chimpanzees (18–45 IU/L). (C) Quantification of serum
CV (1)-stranded RNA by the bDNA assay (Quantiplex-HCV RNA 2.0,
hiron Corp.). The gray area represents viremia levels below the
etection limit (0.2 Meq/ml). (D) Anti-HCV response. Serum anti-HCV
ntibodies were measured in duplicate by the Ortho HCV 3.0 ELISA
est System (Ortho Diagnostic Systems Inc.). The gray area represents
hat anti-HCV response was below the cut-off value (detection limit).etection limit of the bDNA assay (Fig. 2B). The increase
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40 HONG ET AL.n viremia levels during the first 8 weeks could not be
ccounted for from the input inoculum (1 ml of week 5
erum from chimpanzee 3262 with a viral titer of 0.4
eq/ml), suggesting that the circulating HCV RNA could
nly have resulted from actively replicating viruses. The
uccessful transmission of HCV from chimpanzee 3262
o 3261 clearly demonstrated that the circulating HCV
NAs detected in chimpanzee 3262 were from infec-
ious virions of HCV, not from carry-overs of the DNA/
NA inocula.
The second chimpanzee became seroconverted at
eek 9 postintravenous injection (Fig. 2B), slightly earlier
han the first chimpanzee 3262 (at week 13, Fig. 1D).
gain, the timing of the seroconversion coincides with
he drop in viral loads and normalization of the ALT level.
he level of circulating HCV RNA was undetectable even
y RT-PCR at weeks 11–13 and rebounded to RT-PCR
ositive at week 14 (Fig. 2A), with similar fluctuations as
bserved in the first chimpanzee. This offers additional
roof that both chimpanzees have established active
FIG. 2. Transmission of HCV infection to chimpanzee 3261. (A)
T-PCR analysis and weekly ALT levels. A plus sign indicates that
irculating HCV RNA can be detected; a minus sign indicates levels of
irculating HCV RNA below the RT-PCR detection limit. Nested PCR or
T-PCR/Southern blot hybridization may allow detection of this lower
evel of HCV RNA. (B) Quantification of HCV in chimpanzee sera and
nti-HCV serological response. A minus sign indicates that the levels of
nti-HCV antibodies were below the ELISA kit detection limit (less than
he cut-off OD value of 0.678); a plus sign indicates that the chimpanzee
s seropositive for anti-HCV and thus seroconverted.nfection by HCV. sistopathology evaluation of infections in both
himpanzees
For chimpanzee 3262, a liver needle biopsy was ob-
ained at week 13 and evaluated by a veterinary pathol-
gist in a blinded manner. An increase in inflammatory
ells in portal areas with mild piecemeal necrosis was
oted. Small foci of inflammatory cells, primarily lympho-
ytes, were scattered within the parenchyma, sinusoidal
paces, and central veins. Occasional cytoplasmic swell-
ng (ballooning) of hepatocytes with disruption of hepatic
ords was observed. Overall, the finding indicated min-
mal lymphocytic hepatitis in portal areas.
For chimpanzee 3261, the liver needle biopsy was
btained at week 11 and evaluated similarly as above.
ncreased numbers of lymphocytes and macrophages
ere evident in portal areas (Fig. 3A). Aggregates of
nflammatory cells were excessive and tended to invade
nto local hepatic parenchyma. Spotty necrosis of hepa-
ocytes, cytoplasmic swelling, and disruption of sinusoi-
al spaces were observed (Figs. 3B and 3C). Overall, the
inding indicated mild to moderate hepatitis using the
istology activity index (Knodell et al., 1981).
These liver biopsy results were consistent with previ-
usly reported observations (Kolykhalov et al., 1997). The
bility to cause hepatitis in an authentic fashion sug-
ests that our infectious clone is competent in replica-
ion.
he repaired clone shares greater consensus with
ther HCV isolates than the reported isogenic clones
As our repaired clone was derived from the H77 iso-
ate, its sequence was compared with the isogenic clone
eported by Kolykhalov et al. (1997; GenBank Accession
o. AF009606). The comparison revealed that there are a
otal of 43 mismatches at the RNA level between the two
nfectious clones; 38 of them are synonymous varia-
ions and the remaining 5 result in four mismatches at
he protein level (Table 2). All mismatches occur within
he ORF. The 59UTR and 39UTR are identical to the
sogenic clone with a 133-base poly(U/UC) tract. The
ismatch in the NS5A region, at position 2283 (amino
cid position according to the H77 isolate) between P
proline) and R (arginine), requires two nucleotide
hanges at the RNA level. Comparisons with 16 isolates
f different genotypes demonstrated that among the 4
ismatched amino acids in our repaired clone pET/T7/
CV-H, denoted HCV-1a (H/sp), 3 share consensus (in
lue) with other HCV isolates and one in E2 region is
hared by several other HCV isolates, representing a
eutral change (in green). Interestingly, the two noncon-
ensus mismatches in NS3, S (serine) at 1358 and S at
436 in red, were shared between the two reported
nfectious clones (Kolykhalov et al., 1997; Yanagi et al.,
997), designated HCV-1a(H/cr) and HCV-1a(H/nih). This
uggests that these two amino acids in HCV-1a(H/cr)
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41HCV INFECTIOUS CLONEepresent a consensus sequence unique to the H77
solate, which are probably quasispecies variations de-
FIG. 3. Histopathology of a liver needle biopsy obtained from HCV infected
himpanzee X261 at week 11. The biopsy was fixed in buffered saline with
ormalin, embedded in paraffin, sectioned, and stained with hematoxylin–
osin. (A) Aggregates of inflammatory cells in the portal areas and in the
arenchyma of the liver (magnification 3 160). (B and C) Enlargements of
reas from A (magnification, 3600). Mild hepatocyte ballooning (swelling of
he cytoplasm) with disruption of the sinusoidal spaces is noted. Apoptotic
ells are present in association with a foci of lymphocytes.ived from the H77 isolate. It is likely that most viruses iarboring the consensus amino acids P and A (alanine)
t the corresponding positions represent dominant qua-
ispecies, which explains why most of the clones have
he two consensus amino acids. HCV is well known to
xhibit quasispecies with asymmetric distribution. Minor
uasispecies have been shown to be able to compete
ith the dominant quasispecies and become dominant
n certain circumstances (Wyatt et al., 1998). During our
epair, we corrected the original clone at 1358 from S to
and at 1436 from S to A, due to the criteria set to look
or “nonconsensus mismatches” based on the consen-
us template built from sequence alignments of 16 iso-
ates. It has been discussed by Yanagi et al. (1997) that in
heir work nine additional clones with 6 mismatches or
ore might have been infectious if tested in chimpan-
ees. It will be interesting to find out whether those
lones have amino acids similar to ours at those posi-
ions described above. The mismatch at position 2283 in
he NS5A region also showed that the P residue in our
epaired clone shares greater consensus with the rest of
he HCV isolates, while the R residue in HCV-1a(H/cr)
nd HCV-1a(H/nih) has less consensus.
A similar comparison to the other isogenic clone re-
orted by Yanagi et al. (GenBank Accession No.
F011753) revealed 8 mismatches at the protein level
nd 67 mismatches at the RNA level (excluding the
ariations in the poly(U/UC) tract). Four of the amino acid
ismatches were shared by HCV-1a(H/cr) and HCV-
a(H/nih); 4 of them were unique to HCV-1a(H/nih). Two
f these unique mismatches in our clone, E (glutamic
cid) at position 1202 and Q (glutamine) at position 1742,
hare consensus with other HCV isolates, whereas the
orresponding G (glycine) and H (histidine) in HCV-1a(H/
ih) are nonconsensus amino acids, possibly deriving
rom RT/PCR mutations or quasimutations. Nevertheless,
he HCV-1a(H/nih) clone did generate infectious viruses
nd resulted in development of hepatitis in chimpanzee
Yanagi et al., 1997). This suggests that HCV infection can
olerate some degree of nonconsensus mutations, al-
hough building consensus sequences is critical in ob-
aining the infectious clones.
At present, the two reported clones as well as our
epaired clone have been shown to produce infectious
ranscripts and they all originated from the same isolate,
77. Many mismatches at the RNA level are synonymous
ubstitutions and well tolerated. An intriguing experiment
o pursue will be to compare the infectivity of all three
sogenic infectious clones in chimpanzees.
With the infectious molecular clones, it will be possible
o obtain homogeneous viral inocula at early weeks.
uch viral inocula will be useful to address whether
mmunity can be established to protect reinfection by the
ame homogeneous source of virus. A recent study by
yatt et al. (1998) demonstrated that chimpanzees can
e reinfected by minor quasispecies in the same viral
noculum. Our RNA-infected chimpanzee (3262) has es-
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42 HONG ET AL.ablished chronic infection for more than 11 months; the
ransmission-infected chimpanzee (3261) is currently
nder study and remains infected. Long-term follow-up
tudies of both chimpanzees will yield useful information
n the evolution of quasispecies in relation to immune
vasion.
MATERIALS AND METHODS
lasmids, chemicals, and sources of HCV cDNA
lones
All of the cloning vectors were purchased from com-
ercial sources: pET-based vectors are from Novagen,
nc., pGEM-based vectors are from Promega Corp., and
QE-based vectors are from Qiagen, Inc. Most of the
estriction enzymes were from New England Biolabs.
CR was performed using Pfu DNA polymerase (Strat-
gene, CA). Most of the oligomers were synthesized by
enoSys Biotechnologies, Inc. Synthetic RNA primers
ere purchased from Oligos Etc., Inc.
Two HCV cDNA clones were obtained: pBRTM/HCV1-
011 from Dr. Charles M. Rice at Washington University
t St. Louis and pRc/CMV/HCV-H from Dr. Alfred Prince
t the New York Blood Center. pBRTM/HCV1-3011 con-
ains only the ORF of the HCV H77 isolate, whereas the
sogenic clone pRc/CMV/HCV-H consists of the 59UTR
lus the entire ORF. Both clones were sequenced and
erified.
The 39UTR of HCV containing the 133 poly(U/UC) tract
ollowed by the 39X region was synthesized by GenoSys
iotechnologies, Inc. and cloned into pGEM3Zf(2).
n vitro transcription
The final full-length HCV cDNA clone was linearized by
baI and the overhangs were removed by mung bean
uclease. Ten micrograms of linearized DNA was tran-
cribed to produce full-length RNA transcripts using the
arge-scale T7 transcription kit (Novagen, Inc.). The qual-
ty of in vitro transcribed RNA was evaluated on the 1%
garose gel and approximately 80% of the transcripts
ere full-length or near full-length RNAs.
ntrahepatic inoculation of RNA transcripts
Approximately 150 mg of RNA transcripts in the tran-
cription reaction mixture was diluted with 4 vol of ice-
old RNase-free phosphate-buffered saline. Intrahepatic
njection was guided by ultrasound as described (Yanagi
t al., 1998). Each RNA inoculum was injected at three
eparate sites of the liver.
T-PCR and Southern blot hybridization
Serum sample processing, RNA extraction, RT-PCR
nalysis, and Southern blot hybridization were performed
ccording to methods described previously (Bassett et
l., 1998). CDNA assay
The circulating HCV RNAs were quantified by using
he bDNA assay (Quantiplex HCV RNA 2.0 Assay, Chiron
iagnostics). The assay was performed according to the
anufacturer’s instructions. The detection limit is 0.2
eq of HCV RNA per milliliter.
nti-HCV serological response
Chimpanzee sera were analyzed for anti-HCV antibod-
es by using the enzyme-linked immunosorbent assay
ELISA Testing System 3.0, Ortho Diagnostic Systems,
J). The assay was performed according to the manu-
acturer’s instructions. The cut-off value for the ELISA
ssay was determined to be equal to or less than an
bsorbance value (OD) of 0.678 (gray area). Samples
ith the OD value greater than the cut-off value (above
ray area) are considered to be seropositive for anti-HCV
nfection.
equence analysis
All sequencing reactions were carried out by using the
BI Prism BigDye Terminator Cycle Sequencing Ready
eaction Kit (PE Applied Biosystems, Foster City, CA).
rocessed PCR products were analyzed by electro-
horesis using the ABI Prism 377 DNA Sequencer with
L upgrade gel (PE Applied Biosystems). All sequencing
ata were analyzed by using the AutoAssembler soft-
are (version 1.4, PE Applied Biosystems).
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